Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2021-2023

Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2021-2023

The Board of Directors of Revenio Group Corporation has decided, on the basis of the share issue authorization granted to the Board of Directors by the company's Annual General Meeting held on April 8, 2022, to issue shares in a directed share issue without payment to pay the shares from the 2021 earnings period earned by the company’s subsidiary Oculo’s key persons during the performance period 2021-2023 of the share-based incentive scheme.

The arrangement is established to form part of the long-term incentive and commitment program for certain key employees of Oculo. The aim of the arrangement is to support the implementation of the company´s strategy, combine the interests of the shareholders and the participants in order to increase the value and performance of the company in the long-term, to commit participants to the Company after the acquisition. The maximum number of shares in the program is limited. Under the program, shares will be issued for a maximum total value of AUD 1,660,000, calculated at the trading-weighted average price on the closing date April 27, 2021 of the Oculo acquisition. The Arrangement is a three-year performance share plan for the calendar years 2021, 2022 and 2023, respectively.

A total of 1,579 of the company’s treasury shares will be transferred in a directed issue free of charge to persons included in the share-based incentive scheme. After the transfers, the company holds 100,742 treasury shares.

For further information, please contact
President and CEO Jouni Toijala, tel. +358 50 484 0085
[email protected]

CFO Robin Pulkkinen, tel. +358 50 505 9932
[email protected]

Distribution
Nasdaq Helsinki Ltd
Financial Supervisory Authority
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.